We have located links that may give you full text access.
Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series.
Annals of Internal Medicine 2011 January 5
BACKGROUND: Small case series suggest that a combination of mycophenolate mofetil and prednisone may be an effective treatment for patients with retroperitoneal fibrosis.
OBJECTIVE: To describe the outcomes of adults with retroperitoneal fibrosis who received a combination of prednisone and mycophenolate mofetil.
DESIGN: Prospective case series of patients followed between 1 April 2005 and 1 July 2009.
SETTING: Single tertiary care facility.
PATIENTS: 28 patients with retroperitoneal fibrosis.
INTERVENTION: Prednisone, 40 mg/d, tapered over 6 months, and mycophenolate mofetil, 1000 mg twice daily, for a mean of 24.3 months.
MEASUREMENTS: Clinical course, laboratory assessment, and measurement of periaortic mass. Mean follow-up was 1012 days, and no patients were lost to follow-up.
RESULTS: Systemic symptoms resolved in all patients; 89% had a 25% or greater reduction in periaortic mass. Elevated erythrocyte sedimentation rate and serum creatinine level and decreased hemoglobin level normalized in all patients. Disease recurred in 2 of 28 patients.
LIMITATION: This was a small case series.
CONCLUSION: Combined prednisone and mycophenolate mofetil therapy is a potentially effective treatment for retroperitoneal fibrosis that warrants evaluation in randomized trials.
PRIMARY FUNDING SOURCE: None.
OBJECTIVE: To describe the outcomes of adults with retroperitoneal fibrosis who received a combination of prednisone and mycophenolate mofetil.
DESIGN: Prospective case series of patients followed between 1 April 2005 and 1 July 2009.
SETTING: Single tertiary care facility.
PATIENTS: 28 patients with retroperitoneal fibrosis.
INTERVENTION: Prednisone, 40 mg/d, tapered over 6 months, and mycophenolate mofetil, 1000 mg twice daily, for a mean of 24.3 months.
MEASUREMENTS: Clinical course, laboratory assessment, and measurement of periaortic mass. Mean follow-up was 1012 days, and no patients were lost to follow-up.
RESULTS: Systemic symptoms resolved in all patients; 89% had a 25% or greater reduction in periaortic mass. Elevated erythrocyte sedimentation rate and serum creatinine level and decreased hemoglobin level normalized in all patients. Disease recurred in 2 of 28 patients.
LIMITATION: This was a small case series.
CONCLUSION: Combined prednisone and mycophenolate mofetil therapy is a potentially effective treatment for retroperitoneal fibrosis that warrants evaluation in randomized trials.
PRIMARY FUNDING SOURCE: None.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app